Beta Drugs Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Beta Drugs.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Beta Drugs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2023 | 2,560 | 348 | 113 | 277 | N/A |
| 6/30/2023 | 2,416 | 327 | 83 | 255 | N/A |
| 3/31/2023 | 2,271 | 307 | 52 | 234 | N/A |
| 12/31/2022 | 2,176 | 298 | N/A | N/A | N/A |
| 9/30/2022 | 2,081 | 289 | 41 | 265 | N/A |
| 6/30/2022 | 1,960 | 269 | 72 | 281 | N/A |
| 3/31/2022 | 1,838 | 248 | 102 | 296 | N/A |
| 12/31/2021 | 1,683 | 216 | N/A | N/A | N/A |
| 9/30/2021 | 1,528 | 183 | 117 | 218 | N/A |
| 6/30/2021 | 1,345 | 150 | 123 | 202 | N/A |
| 3/31/2021 | 1,161 | 117 | 128 | 186 | N/A |
| 12/31/2020 | 1,058 | 106 | N/A | N/A | N/A |
| 9/30/2020 | 956 | 95 | 21 | 138 | N/A |
| 6/30/2020 | 932 | 94 | -24 | 111 | N/A |
| 3/31/2020 | 908 | 94 | -69 | 84 | N/A |
| 9/30/2019 | 832 | 97 | N/A | N/A | N/A |
| 6/30/2019 | 746 | 89 | N/A | N/A | N/A |
| 3/31/2019 | 659 | 80 | -206 | 1 | N/A |
| 3/31/2018 | 506 | 68 | 88 | 171 | N/A |
| 3/31/2017 | 417 | 43 | N/A | 47 | N/A |
| 3/31/2016 | 264 | 11 | N/A | -4 | N/A |
| 3/31/2015 | 3 | -1 | N/A | 14 | N/A |
| 3/31/2014 | 14 | 0 | N/A | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BETA's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if BETA's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if BETA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BETA's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if BETA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BETA's Return on Equity is forecast to be high in 3 years time